Rathbones Group has suspended the take-on of new clients needing enhanced due diligence and has also halted some fresh money from existing higher-risk clients. The […]
Lorem ipsum dolor sit amet consectetur adipiscing elit inceptos senectus, laoreet ornare semper sapien vel enim purus molestie sem cras, ut velit nisi nullam congue […]
Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), reported the sale of 10,000 shares of common stock for a total consideration of approximately $345,000 on […]